UroGen Pharma (URGN) Amortization of Deferred Charges (2020 - 2026)
UroGen Pharma's (URGN) quarterly Amortization of Deferred Charges came in at $577000.0 in Q1 2026, up 35.76% YoY from $425000.0 in Q1 2025, and down 4.47% on a QoQ basis from $604000.0 in Q4 2025.
UroGen Pharma (URGN) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 7 years of Amortization of Deferred Charges data on file, last reported at $577000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 35.76% year-over-year to $577000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 114.04% YoY) and the FY2025 annual result came in at $2.1 million, up 145.51% from the prior year.
- Amortization of Deferred Charges retreated to $577000.0 in Q1 2026, from $604000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $604000.0 in Q4 2025 to a low of $193000.0 in Q2 2024.
- A 5-year average of $313764.7 and a median of $234000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges dropped 16.6% — and 2025, when it soared 182.32%.
- Tracing URGN's Amortization of Deferred Charges over 5 years: stood at $214000.0 in 2022, then gained by 9.35% to $234000.0 in 2023, then increased by 1.71% to $238000.0 in 2024, then soared by 153.78% to $604000.0 in 2025, then declined by 4.47% to $577000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $577000.0 (Q1 2026), $604000.0 (Q4 2025), and $559000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 590,000.00 |
| Jun 30, 2026 | 590,000.00 |
| Mar 31, 2026 | 577,000.00 |
| Mar 31, 2026 | 577,000.00 |
| Dec 31, 2025 | 604,000.00 |
| Dec 31, 2025 | 604,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Sep 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 516,000.00 |
| Jun 30, 2025 | 516,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 238,000.00 |
| Dec 31, 2024 | 238,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Sep 30, 2024 | 198,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |